A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Taiho Pharmaceutical Co., Ltd.
OHSU Knight Cancer Institute
Nektar Therapeutics
AstraZeneca
Royal Marsden NHS Foundation Trust